Innovative Therapeutics Carmot Therapeutics is advancing a broad pipeline of clinical candidates targeting obesity and diabetes, combining proprietary drug discovery platforms with clinical-stage development, signaling opportunities for partnerships in metabolic health solutions.

Strong Financial Backing With recent Series D funding of $160 million and a total funding of $150 million, Carmot has substantial financial resources to accelerate clinical trials and expand collaborations, making it an attractive partner for organizations seeking innovative metabolic therapies.

Market Expansion Potential As a member of Roche since early 2024, Carmot benefits from Roche’s extensive global reach, providing opportunities to co-develop and commercialize novel therapeutics in metabolic diseases and potentially other areas like cancer.

Focus on Metabolic Diseases Carmot's emphasis on developing treatments for obesity and diabetes aligns with rising market demand, creating opportunities for healthcare providers and pharmaceutical companies to integrate its novel therapeutics into existing treatment workflows.

Small but Strategic Team Operating with a compact team of 2-10 employees, Carmot offers a highly agile environment for collaborative innovation, making it a strategic partner for biotech firms and organizations interested in cutting-edge drug discovery technology.